Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 23%
Buy 8%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health Inc is experiencing significant growth, highlighted by a 70% year-over-year subscriber increase in Q4, suggesting strong demand for its telehealth services across various specialties, including weight loss and sexual health. The company's international portfolio and strategic partnerships, such as access to potential new weight loss drugs, are expected to contribute positively to future revenue growth, with adjustments anticipated to enhance margins and performance. Additionally, Hims & Hers is diversifying its offerings, reducing concentration risk by not solely relying on specific market narratives, thus positioning itself favorably for sustained revenue normalization in alignment with subscriber growth trends.

Bears say

Hims & Hers Health Inc. is facing a negative outlook primarily due to significantly slowing revenue growth, as evidenced by its disappointing 4Q:25 earnings results and weak guidance for 1Q:26. The company has reduced its full-year 2026 revenue estimates, now expected at $2.7 billion to $2.9 billion, compared to prior expectations, indicating a lack of momentum. Additionally, the increased legal and regulatory risks further compound concerns about the company's financial stability and future performance.

HIMS has been analyzed by 13 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 8% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Hold based on their latest research and market trends.

According to 13 analysts, HIMS has a Hold consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.